RA
LGND icon

Royce & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Royce & Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,897
Closed -$310K – 837
2024
Q4 		$310K Sell
2,897
-3,193
-52% -$361K ﹤0.01% 788
2024
Q3 		$610K Sell
6,090
-4,996
-45% -$503K 0.01% 781
2024
Q2 		$934K Sell
11,086
-4,038
-27% -$321K 0.01% 724
2024
Q1 		$1.11M Sell
15,124
-5,037
-25% -$371K 0.01% 713
2023
Q4 		$1.44M Buy
20,161
+7,450
+59% +$440K 0.01% 694
2023
Q3 		$762K Buy
12,711
+6,325
+99% +$416K 0.01% 772
2023
Q2 		$460K Buy
+6,386
New +$479K ﹤0.01% 847
2020
Q1 		– Sell
-721
Closed -$47K – 1175
2019
Q4 		$47K Sell
721
-206
-22% -$13.8K ﹤0.01% 1046
2019
Q3 		$58K Buy
927
+414
+81% +$26K ﹤0.01% 1036
2019
Q2 		$37K Buy
513
+32
+7% +$2.36K ﹤0.01% 1059
2019
Q1 		$38K Sell
481
-18,755
-97% -$1.42M ﹤0.01% 1063
2018
Q4 		$1.63M Buy
+19,236
New +$2.05M 0.01% 785
2018
Q1 		– Sell
-112
Closed -$10K – 1267
2017
Q4 		$10K Buy
112
+13
+13% +$1.13K ﹤0.01% 1175
2017
Q3 		$8K Buy
+99
New +$7.84K ﹤0.01% 1189

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's LGND Position: Q1 2025 in Review

Royce & Associates sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 2,897 shares — an estimated $310K sold.

Royce & Associates first reported a position in LGND in Q3 2017 and held it in 14 quarters. The position peaked at $1.63M in Q4 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • Royce & Associates reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Royce & Associates sold 2,897 Ligand Pharmaceuticals shares in Q1 2025, an estimated $310K.
  • Royce & Associates first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 14 quarters.
  • Royce & Associates's Ligand Pharmaceuticals position peaked at $1.63M in Q4 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Royce & Associates's 13F filing for Q1 2025, filed 6 May 2025.